Pliant Therapeutics reported related party revenue of $4.8 million for the third quarter of 2020, compared to none for the prior-year quarter. Research and development expenses were $16.9 million, and net loss was $16.5 million. The company had cash, cash equivalents, and short-term investments of $294.0 million as of September 30, 2020.